Grifols collaborates with start-up FcR Therapeutics

5 February 2025

Spanish plasma-derived medicines specialist Grifols (MCE:GRF) revealed it is collaborating with Dutch biotechnology start-up, FcR Therapeutics, to develop recombinant nanobodies to treat autoimmune diseases.

The nanobodies, which are small highly specialized antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that play a crucial role in immune responses, such as driving inflammation or pathogen neutralization.

Grifols said it is helping seed the work of FcR Therapeutics, based in Utrecht, the Netherlands, in addition to contributing its vast knowledge of immunoglobulins, the human immune system and recombinant proteins. No financial terms of the accord were disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK